Somewhat Favorable News Coverage Somewhat Unlikely to Affect Ekso Bionics (EKSO) Share Price
Media headlines about Ekso Bionics (NASDAQ:EKSO) have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ekso Bionics earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.3568088554653 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Ekso Bionics Holdings, Inc. (EKSO) : Investor is seeking for stock with consensus Analysts Rating? – Wall Street Morning (wallstreetmorning.com)
- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Stock’s Liquidity Overview – Nasdaq Journal (press release) (nasdaqjournal.com)
- Comprehensive Stock Analysis – Ekso Bionics Holdings, Inc., (NASDAQ: EKSO) – Stock Watch (stocksnewstimes.com)
- Medical Robots Market – Outlook,Trends 2025 (mynewsdesk.com)
Ekso Bionics (NASDAQ:EKSO) remained flat at $$2.13 during mid-day trading on Friday. 399,643 shares of the stock were exchanged, compared to its average volume of 1,885,689. The company has a quick ratio of 5.73, a current ratio of 6.09 and a debt-to-equity ratio of 0.18. Ekso Bionics has a 12-month low of $0.99 and a 12-month high of $4.77. The company has a market capitalization of $127.60, a PE ratio of -1.88 and a beta of -0.07.
EKSO has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Ekso Bionics from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research note on Thursday, September 7th. ValuEngine raised shares of Ekso Bionics from a “strong sell” rating to a “sell” rating in a research note on Friday, November 17th.
In other news, insider Russ Angold sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total value of $175,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.32% of the stock is owned by corporate insiders.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.